Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

Delayed Quote. Delayed  - 08/23 10:00:00 pm
12.25 USD   -1.92%
08/23 VANDA PHARMACEU : HETLIOZ Now Available for Treatment of Non-24-Hour..
08/01 VANDA PHARMACEU : HETLIOZ® is Now Available for the Treatment of Non..
07/27 VANDA PHARMACEU : reports 2Q loss
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Vanda To Pay Eli Lilly Up To $100 Million In Drug Development Agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/16/2012 | 01:50pm CEST

Vanda Pharmaceuticals Inc. (>> Vanda Pharmaceuticals Inc.) agreed to pay Eli Lilly Co. (LLY) up to $100 million for the exclusive right to develop a drug that has shown some promise as a treatment for alcohol addiction.

Under its deal with Lilly, the biopharmaceutical company will pay a $1 million initial license fee and take responsibility for all development costs of the VLY-686 drug.

Lilly is also eligible to receive additional payments based upon certain milestones and royalties on sales. These milestones include $4 million for milestones achieved prior to a new drug application and up to $95 million for future regulatory approval and sales milestones.

Vanda, which focuses on treatments for central nervous system disorders, noted that prior research of VLY-686 has focused on its potential as a novel therapeutic for individuals struggling with dependence on alcohol.

"The licensing of VLY-686 is an important milestone for Vanda, as we continue to realize our vision of developing treatments to address unmet medical needs," said Chief Executive Mihael H. Polymeropoulos.

Vanda in February reported it swung to a loss in the fourth quarter as increased expenses outweighed higher revenue for the period.

Shares closed Friday at $4.49 and were inactive in premarket trade. The stock has slumped 42% over the past year.

-By Mia Lamar, Dow Jones Newswires; 212-416-3207; mia.lamar@dowjones.com

Stocks mentioned in the article : Vanda Pharmaceuticals Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VANDA PHARMACEUTICALS INC.
08/23 VANDA PHARMACEUTICALS : HETLIOZ Now Available for Treatment of Non-24-Hour Sleep..
08/18 VANDA PHARMACEUTICALS : "Treating Neurodegenerative Disease with Fenofibrate and..
08/11 VANDA PHARMACEUTICALS : Assigned Patent
08/01 VANDA PHARMACEUTICALS INC. : Other Events, Financial Statements and Exhibits (fo..
08/01 VANDA PHARMACEUTICALS : HETLIOZ® is Now Available for the Treatment of Non-24-Ho..
07/28 VANDA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
07/27 VANDA PHARMACEUTICALS : reports 2Q loss
07/27 VANDA PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Fina..
07/27 VANDA PHARMACEUTICALS : Reports Second Quarter 2016 Financial Results
07/12 VANDA PHARMACEUTICALS : to Announce Second Quarter 2016 Financial Results on Jul..
More news
Sector news : Bio Therapeutic Drugs
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
08/22DJPFIZER : to Acquire Medivation in Deal Worth $14 Billion -- 4th Update
08/22DJPFIZER : to Acquire Medivation in Deal Worth $14 Billion -- 3rd Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08/20 Tracking John Paulson's Paulson & Company Portfolio - Q2 2016 Update
08/19 BIOTECH FORUM DAILY DIGEST : Portola's Big Disappointment, Cerulean Implodes, Sp..
07/27 Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q2 2016 Results - ..
07/27 Vanda Pharmaceuticals beats by $0.24, revenue in-line
07/26 Notable earnings after Wednesday?s close
Advertisement
Financials ($)
Sales 2016 147 M
EBIT 2016 -31,2 M
Net income 2016 -25,9 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 3,69x
Capi. / Sales 2017 3,25x
Capitalization 541 M
More Financials
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Full-screen chart
Technical analysis trends VANDA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 17,3 $
Spread / Average Target 38%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Senior VP
Paolo Baroldi Chief Medical Officer & Senior Vice President
Howard H. Pien Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS ..34.16%541
AMGEN, INC.7.40%130 477
GILEAD SCIENCES, INC.-20.03%106 787
CELGENE CORPORATION-4.64%88 518
REGENERON PHARMACEUTIC..-22.88%44 082
VERTEX PHARMACEUTICALS..-19.76%25 016
More Results